Shane Needham discusses how high-resolution mass spectrometry is helping labs meet the evolving demands of peptide therapeutics.

Our President and CEO, Shane Needham, PhD, was recently featured in The Analytical Scientist discussing the impact of GLP-1 receptor agonists and emerging peptide therapeutics on bioanalytical workflows. As peptide programs demand lower quantification limits, smaller sample volumes and faster method development, the interview explores how high-resolution accurate-mass (HRAM) technology complements traditional triple quadrupole platforms to improve selectivity, confidence and speed.

Read the full interview here.